Cybin Company Presentation

Global mushroom medicinal mushroom market expected to exceed US$13.9B annually by 2022 (1) (1 ) (2) I T ’ S N O T M A G I C , I T ’ S M U S H R O O M S ™ Journey™ Nutraceutical Mushroom Products for the Millennial Generation 19 P r i v a t e & C o n f i d e n t i a l (3) Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement Regarding Forward-Looking Information” on page 2 of this presentation. (4) Packaging is conceptual and may not adhere to requirements of applicable legislation of certain territories Over 20 custom formulated products (Mushrooms & Adaptogens) Medicinal Global nutraceutical market to reach $722B by 2027 (2) Trademarks include Journey™, Mushroom & Friends™ and It’s not magic. Its mushrooms™ Exclusive formulation rights to some of the most clinically studied medicinal mushroom extracts such as Active Hexose Correlated Compound (“AHCC”) Form factors will include capsules, hard tablets, infused coffees, infused teas, powders and other patent pending delivery mechanisms (3) Targeting cognitive flexibility, mental wellness, immune boosting, energy and detoxification (3) (5) Launch strategy geared towards e-commerce sales. Our digital team has vast online sales experience (3) Goal is to become a top millennial driven mushroom nutraceutical brand and to garner a large social media reach across North America (3) (4) (5) Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by FDA-approved research. There is no assurance thatpsilocybin can be used to diagnose, treat, cure or prevent any disease or conditionand robust scientific research and clinical trials are needed.